Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
31.07%
operating margin TTM
28.32%
revenue TTM
13.23 Billion
revenue per share TTM
123.05$
valuation ratios | |
|---|---|
| pe ratio | 15.46 |
| peg ratio | -2.84 |
| price to book ratio | 1.95 |
| price to sales ratio | 4.80 |
| enterprise value multiple | 13.76 |
| price fair value | 1.95 |
profitability ratios | |
|---|---|
| gross profit margin | 84.47% |
| operating profit margin | 28.32% |
| pretax profit margin | 33.66% |
| net profit margin | 31.07% |
| return on assets | 11.69% |
| return on equity | 14.77% |
| return on capital employed | 10.89% |
liquidity ratio | |
|---|---|
| current ratio | 33.45 |
| quick ratio | 29.66 |
| cash ratio | 0.00 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 510.98 |
| operating cycle | 670.63 |
| days of payables outstanding | 130.67 |
| cash conversion cycle | 539.96 |
| receivables turnover | 2.29 |
| payables turnover | 2.79 |
| inventory turnover | 0.71 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.05 |
| debt equity ratio | 0.06 |
| long term debt to capitalization | 0.05 |
| total debt to capitalization | 0.05 |
| interest coverage | 72.86 |
| cash flow to debt ratio | 2.23 |
cash flow ratios | |
|---|---|
| free cash flow per share | 33.43 |
| cash per share | 166.47 |
| operating cash flow per share | 41.08 |
| free cash flow operating cash flow ratio | 0.81 |
| cash flow coverage ratios | 2.23 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 5.37 |
Frequently Asked Questions
When was the last time Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported earnings?
Regeneron Pharmaceuticals, Inc. (REGN) published its most recent earnings results on 05-02-2025.
What is Regeneron Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s trailing twelve months ROE is 14.77%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Regeneron Pharmaceuticals, Inc. (REGN) currently has a ROA of 11.69%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did REGN's net profit margin stand at?
REGN reported a profit margin of 31.07% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is REGN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 33.45 in the most recent quarter. The quick ratio stood at 29.66, with a Debt/Eq ratio of 0.06.